Black Diamond Financial LLC Purchases New Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR)

Black Diamond Financial LLC purchased a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 277,737 shares of the biotechnology company’s stock, valued at approximately $3,833,000.

Other institutional investors also recently added to or reduced their stakes in the company. New York State Common Retirement Fund boosted its holdings in Capricor Therapeutics by 625.0% in the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 5,000 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in Capricor Therapeutics in the 3rd quarter valued at approximately $161,000. Sassicaia Capital Advisers LLC purchased a new stake in Capricor Therapeutics in the 3rd quarter valued at approximately $192,000. SG Americas Securities LLC boosted its holdings in Capricor Therapeutics by 74.8% in the 4th quarter. SG Americas Securities LLC now owns 15,317 shares of the biotechnology company’s stock valued at $211,000 after purchasing an additional 6,552 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in Capricor Therapeutics by 868.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 15,872 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Price Performance

Shares of NASDAQ:CAPR opened at $15.00 on Monday. The business’s 50 day simple moving average is $14.24 and its 200-day simple moving average is $13.41. The firm has a market capitalization of $682.05 million, a price-to-earnings ratio of -14.15 and a beta of 4.08. Capricor Therapeutics Inc has a 12 month low of $3.52 and a 12 month high of $23.40.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a report on Thursday, January 2nd. Cantor Fitzgerald lifted their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.